AstraZeneca Annual Report and Financial Statements Form 20-F Information 2004 97 22 Net cash inflow from trading operations 2004 2003 2002 $m $m $m Operating profit before exceptional items 4,770 4,111 4,356 Depreciation, amortisation and impairment 1,268 1,290 960 Stocks decrease increase 129 131 101 Debtors increase 209 540 198 Creditors increase decrease 71 430 402 Other non-cash movements including exchange 40 317 65 6,069 4,617 5,686 23 Cash outflow related to exceptional items 2004 2003 2002 Current period cash flow related to exceptional items $m $m $m Synergy and integration costs 25 68 Zoladex OIG settlement 355 Costs relating to disposals and demerger of other businesses 8 11 25 Outflow related to exceptional items 8 391 93 Details of the cash inflows in connection with the profit on the sale of an interest in a joint venture are set out in Note 24.
24 Disposal of business operations 2004 2003 2002 $m $m $m Fixed assets 2 70 Current assets 17 34 Creditors due within one year 7 17 Book value of net assets disposed 12 87 Disposal costs 72 Profit on disposals 274 Less: Cash included in undertakings disposed 3 7 Cash consideration 355 80 The cash consideration is in relation to the sale of the Groups share of the joint venture Advanta BV, which was completed on 1 September 2004 $284m and the disposal of the Durascan business in the first half of the year $71m.
The profit on disposal is stated after transaction costs and warranty provisions.
The sale consideration received in 2003 was in relation to the sale of Marlow Foods Limited, which was completed on 23 May 2003.
